MYC加IIa类HDAC抑制驱动非小细胞肺癌中线粒体功能障碍
Jina Park1, Ying-Yu Chen1, Jennie J Cao2
1Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Cell reports
|May 20, 2025
概括
结合MYC抑制剂与IIa类组素脱乙酶 (HDAC) 抑制剂,显示出治疗非小细胞肺癌 (NSCLC) 的前景. 这种双重向通过抑制MYC和增加线粒体反应性氧物种 (ROS) 来降低癌细胞活力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 向MYCcoprotein至关重要,但对于有效的癌症治疗,需要结合策略.
- 二等级IIa组胺脱乙酶 (HDAC5和HDAC9) 涉及癌症进展,并代表潜在的治疗点.
- 非小细胞肺癌 (NSCLC) 经常表现出高MYC表达和线粒体活性,表明对联合疗法的脆弱性.
研究的目的:
- 为了确定结合MYC抑制用于癌症治疗的新型治疗点.
- 调查MYC和IIa类HDAC在NSCLC中的双重向的有效性.
- 阐明组合疗法的抗瘤作用背后的分子机制.
主要方法:
- 用MYC抑制剂治疗的癌症细胞系的转录组数据分析.
- 在NSCLC细胞系中进行体外活力测定和分子分析 (ROS,MYC水平).
- 在动物模型中进行的体内疗效研究,并进行相关分子分析.
主要成果:
- 鉴定HDAC5和HDAC9作为潜在的治疗点与MYC抑制一起.
- 对MYC和IIa类HDAC的双重向显著降低了NSCLC细胞活力.
- 联合治疗导致MYC抑制,线粒体ROS升高,并证明了体内抗瘤疗效.
结论:
- 针对MYC和IIa类HDAC的组合疗法是NSCLC治疗的一个有希望的策略.
- 这种组合的疗效与MYC枯竭和线粒体功能障碍有关.
- 这种方法为利用NSCLC中的MYC漏洞提供了一个新的治疗途径.
相关概念视频
Electron Transport Chain: Complex I and II
9.9K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.9K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
The Intrinsic Apoptotic Pathway
5.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.8K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


